The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers
Open accessAbstract
Background: The cerebrospinal fluid (CSF) biomarkers amyloid β (Aβ)‐42, total‐tau (T‐tau), and phosphorylated‐tau (P‐tau) demonstrate good diagnostic accuracy for Alzheimer's disease (AD). However, there are large variations in biomarker measurements between studies, and between and within laboratories. The Alzheimer's Association has initiated a global quality control program to estimate and monitor variability of measurements, quantify batch‐to‐batch assay variations, and identify sources of variability. In this article, we present the results from the first two rounds of the program. Methods: The program is open for laboratories using commercially available kits for Aβ, T‐tau, or P‐tau. CSF samples (aliquots of pooled CSF) are sent for analysis several times a year from the Clinical Neurochemistry Laboratory at the Mölndal campus of the University of Gothenburg, Sweden. Each round consists of three quality control samples. Results: Forty laboratories participated. Twenty‐six used INNOTEST enzyme‐linked immunosorbent assay kits, 14 used Luminex xMAP with the INNO‐BIA AlzBio3 kit (both measure Aβ‐(1‐42), P‐tau(181P), and T‐tau), and 5 used Meso Scale Discovery with the Aβ triplex (AβN‐42, AβN‐40, and AβN‐38) or T‐tau kits. The total coefficients of variation between the laboratories were 13% to 36%. Five laboratories analyzed the samples six times on different occasions. Within‐laboratory precisions differed considerably between biomarkers within individual laboratories. Conclusions: Measurements of CSF AD biomarkers show large between‐laboratory variability, likely caused by factors related to analytical procedures and the analytical kits. Standardization of laboratory procedures and efforts by kit vendors to increase kit performance might lower variability, and will likely increase the usefulness of CSF AD biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Self-citationHansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · cited 1×
“Methods: The program is open for laboratories using commercially available kits for Ab, T-tau, or P-tau.”
MethodSelf-citationCSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Self-citationInverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
Self-citationCSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176
Self-citationFagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897 · cited 1×
“They may also be used to identify AD before onset of dementia at the stage of mild cognitive impairment, as shown in both single-center [6–8] and large-scale heterogeneous multicenter studies [9–11], and to predict mild cognitive impairment/AD in those who are cognitively normal [12,13].”
ResultSelf-citationTapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.596 · Cited by 896
Self-citationPET imaging of amyloid deposition in patients with mild cognitive impairment
Forsberg, A., Engler, H., Almkvist, O., Blomquist, G., Hagman, G., Wall, A., Ringheim, A., Långström, B., & Nordberg, A. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.03.029 · Cited by 728
Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF
Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C., Riemenschneider, M., Deyn, P. P. D., Bancher, C., Cras, P., Wiltfang, J., Mehta, P. D., et al. (1999) · Neurology · doi:10.1212/wnl.52.8.1555 · Cited by 724
Self-citationAndreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.673 · Cited by 660
Self-citationSunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656
Visser, P. J., Verhey, F., Knol, D. L., Scheltens, P., Wahlund, L.-O., Freund-Levi, Y., Tsolaki, M., Minthon, L., Wallin, Å. K., Hampel, H., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70139-5 · Cited by 614
Self-citationCSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study
Strozyk, D., Blennow, K., White, L. R., & Launer, L. J. (2003) · Neurology · doi:10.1212/01.wnl.0000046581.81650.d0 · Cited by 612
Self-citationEvaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice
Andreasen, N., Minthon, L., Davidsson, P., Vanmechelen, E., Vanderstichele, H., Winblad, B., & Blennow, K. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.373 · Cited by 573
Self-citationOlsson, A., Vanderstichele, H., Andreasen, N., De Meyer, G., Wallin, A., Holmberg, B., Rosengren, L., Vanmechelen, E., & Blennow, K. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.039347 · Cited by 437
Self-citationStandardization of measurement of β-amyloid(1-42)in cerebrospinal fluid and plasma
Vanderstichele, H., Kerschaver, E. V., Hesse, C., Davidsson, P., Buyse, M.-A., Andreasen, N., Minthon, L., Wallin, A., Blennow, K., & Vanmechelen, E. (2000) · Amyloid · doi:10.3109/13506120009146438 · Cited by 301
Self-citationHampel, H., Teipel, S. J., Fuchsberger, T., Andreasen, N., Wiltfang, J., Otto, M., Shen, Y., Dodel, R., Du, Y., Farlow, M., et al. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001473 · Cited by 287
Self-citationCSF tau/Aβ 42 ratio for increased risk of mild cognitive impairment: A follow-up study
Li, G., Sokal, I., Quinn, J. F., Leverenz, J. B., Brodey, M., Schellenberg, G. D., Kaye, J. A., Raskind, M. A., Zhang, J., Peskind, E. R., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000267428.62582.aa · Cited by 279
Self-citationAndreasen, N., Minthon, L., Vanmechelen, E., Vanderstichele, H., Davidsson, P., Winblad, B., & Blennow, K. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00617-5 · Cited by 239
Self-citationSjögren, M., Minthon, L., Davidsson, P., Granérus, A. K., Clarberg, A., Vanderstichele, H., Vanmechelen, E., Wallin, A., & Blennow, K. (2000) · Journal of Neural Transmission · doi:10.1007/s007020070079 · Cited by 239
Self-citationConfounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid
Bjerke, M., Portelius, E., Minthon, L., Wallin, A., Anckarsäter, H., Anckarsäter, R., Andreasen, N., Zetterberg, H., Andreasson, U., & Blennow, K. (2010) · International Journal of Alzheimer's Disease · doi:10.4061/2010/986310 · Cited by 234
Self-citationMaddalena, A., Papassotiropoulos, A., Müller-Tillmanns, B., Jung, H. H., Hegi, T., Nitsch, R. M., & Hock, C. (2003) · Archives of Neurology · doi:10.1001/archneur.60.9.1202 · Cited by 204
CSF amyloid β42 and tau levels correlate with AIDS dementia complex
Brew, B. J., Pemberton, L., Blennow, K., Wallin, A., & Hagberg, L. (2005) · Neurology · doi:10.1212/01.wnl.0000183293.95787.b7 · Cited by 199
Self-citationCSF Aβ42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment
Herukka, S.-K., Hallikainen, M., Soininen, H., & Pirttilä, T. (2005) · Neurology · doi:10.1212/01.wnl.0000156914.16988.56 · Cited by 189
Self-citationAmyloid β(1–42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease
Schoonenboom, N. S. M., Pijnenburg, Y. A. L., Mulder, C., Rosso, S. M., Van Elk, E. J., Van Kamp, G. J., Van Swieten, J. C., & Scheltens, P. (2004) · Neurology · doi:10.1212/01.wnl.0000123249.58898.e0 · Cited by 181
Decreased β-amyloid 1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease
Otto, M., Esselmann, H., Schulz-Schaeffer, W., Neumann, M., Schröter, A., Ratzka, P., Cepek, L., Zerr, I., Steinacker, P., Windl, O., et al. (2000) · Neurology · doi:10.1212/wnl.54.5.1099 · Cited by 171
Self-citationDecreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies
Kanemaru, K., Kameda, N., & Yamanouchi, H. (2000) · Neurology · doi:10.1212/wnl.54.9.1875 · Cited by 170
Verwey, N. A., van der Flier, W. M., Blennow, K., Clark, C., Sokolow, S., De Deyn, P. P., Galasko, D., Hampel, H., Hartmann, T., Kapaki, E., et al. (2009) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1258/acb.2009.008232 · Cited by 169
Self-citationWallin, A., Blennow, K., Andreasen, N. C., & Minthon, L. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000090631 · Cited by 168
Self-citationTau and Aβ42 protein in CSF of patients with frontotemporal degeneration
Riemenschneider, M., Wagenpfeil, S., Diehl, J., Lautenschlager, N., Theml, T., Heldmann, B., Drzezga, A., Jahn, T., Förstl, H., & Kurz, A. (2002) · Neurology · doi:10.1212/wnl.58.11.1622 · Cited by 168
Schoonenboom, N. S., Mulder, C., Vanderstichele, H., Van Elk, E.-J., Kok, A., Van Kamp, G. J., Scheltens, P., & Blankenstein, M. A. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.039735 · Cited by 165
Self-citationSubgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers
Iqbal, K., Flory, M., Khatoon, S., Soininen, H., Pirttila, T., Lehtovirta, M., Alafuzoff, I., Blennow, K., Andreasen, N., Vanmechelen, E., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20639 · Cited by 163
Self-citationLewczuk, P., Beck, G., Esselmann, H., Bruckmoser, R., Zimmermann, R., Fiszer, M., Bibl, M., Maler, J. M., Kornhuber, J., & Wiltfang, J. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2005.058776 · Cited by 162
Self-citationBiomarkers in Alzheimer's disease drug development
Blennow, K. (2010) · Nature Medicine · doi:10.1038/nm.2221 · Cited by 162
Self-citationAndreasen, N., Vanmechelen, E., Vanderstichele, H., Davidsson, P., & Blennow, K. (2003) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.107.s179.9.x · Cited by 160
Self-citationSjögren, M. J. C., Davidsson, P., Wallin, A., Granérus, A., Grundström, E., Askmark, H., Vanmechelen, E., & Blennow, K. (2002) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000048642 · Cited by 160
Self-citationCerebrospinal fluid markers for prediction of Alzheimer's disease
Zetterberg, H., Wahlund, L.-O., & Blennow, K. (2003) · Neuroscience Letters · doi:10.1016/j.neulet.2003.08.011 · Cited by 158
Self-citationOlsson, A., Höglund, K., Sjögren, M. J. C., Andreasen, N., Minthon, L., Lannfelt, L., Büerger, K., Möller, H., Hampel, H. J., Davidsson, P., et al. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00027-x · Cited by 151
Self-citationKapaki, E., Kilidireas, K., Paraskevas, G. P., Michalopoulou, M., & Patsouris, E. (2001) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.71.3.401 · Cited by 144
Self-citationCerebrospinal Fluid Markers in Dementia With Lewy Bodies Compared With Alzheimer Disease
Gómez‐Tortosa, E., Gonzalo, I., Fanjul, S., Sainz, M. J., Cantarero, S., Cemillán, C. A., de Yébenes, J. G., & del Ser, T. (2003) · Archives of Neurology · doi:10.1001/archneur.60.9.1218 · Cited by 135
Lee, J., Blennow, K., Andreasen, N., Laterza, O., Modur, V., Olander, J. V., Gao, F., Ohlendorf, M. F., & Ladenson, J. H. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.104497 · Cited by 132
Self-citationAPOE ε4 allele is associated with reduced cerebrospinal fluid levels of Aβ42
Prince, J. A., Zetterberg, H., Andreasen, N., Marcusson, J., & Blennow, K. (2004) · Neurology · doi:10.1212/01.wnl.0000128088.08695.05 · Cited by 128
Self-citationSjögren, M. J. C., Davidsson, P., Gottfries, J., Vanderstichele, H., Edman, Å., Vanmechelen, E., Wallin, A., & Blennow, K. (2001) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051268 · Cited by 122
Self-citationIncreased cerebrospinal fluid levels of transforming growth factor-β1 in Alzheimer’s disease
Zetterberg, H., Andreasen, N., & Blennow, K. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.06.001 · Cited by 111
Self-citationInternational quality control survey of neurochemical dementia diagnostics
Lewczuk, P., Beck, G., Ganslandt, O., Esselmann, H., Deisenhammer, F., Regeniter, A., Petereit, H.-F., Tumani, H., Gerritzen, A., Oschmann, P., et al. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.07.009 · Cited by 107
Self-citationJia, J., Meng, R., Sun, Y., Sun, W., Ji, X., & Jia, L. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.03.051 · Cited by 104
Bibl, M., Esselmann, H., Otto, M., Lewczuk, P., Cepek, L., Rüther, E., Kornhuber, J., & Wiltfang, J. (2004) · Electrophoresis · doi:10.1002/elps.200305992 · Cited by 101
Self-citationMollenhauer, B., Cepek, L., Bibl, M., Wiltfang, J., Schulz‐Schaeffer, W., Ciesielczyk, B., Neumann, M., Steinacker, P., Kretzschmar, H. A., Poser, S., et al. (2005) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000083178 · Cited by 99
Self-citationFrisoni, G. B., & Jack, C. R. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.06.007 · Cited by 98
Self-citationMaruyama, M., Arai, H., Sugita, M., Tanji, H., Higuchi, M., Okamura, N., Matsui, T., Higuchi, S., Matsushita, S., Yoshida, H., et al. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7814 · Cited by 97
Self-citationKapaki, E., Paraskevas, G. P., Zalonis, I., & Zournas, C. (2003) · European Journal of Neurology · doi:10.1046/j.1468-1331.2003.00562.x · Cited by 91
Self-citationRiemenschneider, M. J., Schmolke, M., Lautenschlager, N. T., Guder, W. G., Vanderstichele, H., Vanmechelen, E., & Kurz, A. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)00976-9 · Cited by 90
Self-citationNoguchi, M., Yoshita, M., Matsumoto, Y., Ono, K., Iwasa, K., & Yamada, M. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.05.015 · Cited by 83
Nägga, K., Gottfries, J., Blennow, K., & Marcusson, J. O. (2002) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000066023 · Cited by 79
Self-citationMollenhauer, B., Bibl, M., Wiltfang, J., Steinacker, P., Ciesielczyk, B., Neubert, K., Trenkwalder, C., & Otto, M. (2006) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2006.035 · Cited by 79
Self-citationRosso, S. M., van Herpen, E., Pijnenburg, Y. A. L., Schoonenboom, N. S. M., Scheltens, P., Heutink, P., & Swieten, J. C. V. (2003) · Archives of Neurology · doi:10.1001/archneur.60.9.1209 · Cited by 78
Diagnostic Accuracy of ELISA and xMAP Technology for Analysis of Amyloid β42 and Tau Proteins
Reijn, T. S., Rikkert, M. G. M. O., van Geel, W. J. A., de Jong, D., & Verbeek, M. M. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.081679 · Cited by 73
Self-citationTeunissen, C. E., Verwey, N. A., Kester, M. I., van Uffelen, K. W. J., & Blankenstein, M. A. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/635053 · Cited by 72
Self-citationIbach, B., Binder, H., Dragon, M., Poljansky, S., Haen, E., Schmitz, E., Koch, H., Putzhammer, A., Kluenemann, H., Wieland, W. F., et al. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.06.005 · Cited by 69
Stefani, A., Bernardini, S., Panella, M., Pierantozzi, M., Nuccetelli, M., Koch, G., Urbani, A., Giordano, A., Martorana, A., Orlacchio, A., et al. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.05.016 · Cited by 66
Self-citationIvanoiu, A., & Sindic, C. J. M. (2005) · Neurocase · doi:10.1080/13554790490896901 · Cited by 60
Characterization of a New Certified Reference Material for Human Cardiac Troponin I
Bunk, D. M., & Welch, M. J. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2005.051359 · Cited by 55
Rösler, N., Wichart, I., & Jellinger, K. A. (2001) · Journal of Neural Transmission · doi:10.1007/s007020170091 · Cited by 51
Bunk, D. M. (2007) · PubMed · Cited by 47
CSF markers related to pathogenetic mechanisms in Alzheimer's disease
Mulder, C., Schoonenboom, S. N. M., Wahlund, L., Scheltens, P., van Kamp, G. J., Veerhuis, R., Hack, C. E., Blomberg, M. E., Schutgens, R. B. H., & Eikelenboom, P. (2002) · Journal of Neural Transmission · doi:10.1007/s00702-002-0763-y · Cited by 43
CSF tau and Aβ42 are not useful in the diagnosis of frontotemporal lobar degeneration
Pijnenburg, Y. A. L., Schoonenboom, N. S. M., Rosso, S. M., Mulder, C., van Kamp, G. J., Swieten, J. C. V., & Scheltens, P. (2004) · Neurology · doi:10.1212/01.wnl.0000123014.03499.a7 · Cited by 35
Briani, C., Ruggero, S., Naccarato, M., Cagnin, A., Ricchieri, G., Pasqui, L., Pizzolato, G., & Battistin, L. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200031 · Cited by 16
Cited by
Welsh, J. A., Goberdhan, D. C. I., O'Driscoll, L., Buzas, E. I., Blenkiron, C., Bussolati, B., Cai, H., Di Vizio, D., Driedonks, T. A. P., Erdbrügger, U., et al. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12404 · Cited by 4,663
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationBiomarkers for Alzheimer's disease: current status and prospects for the future
Blennow, K., & Zetterberg, H. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12816 · Cited by 1,000
Self-citationThe Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Liu, E., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.05.1769 · Cited by 1,010
Self-citationHansson, O., Seibyl, J., Stomrud, E., Zetterberg, H., Trojanowski, J. Q., Bittner, T., Lifke, V., Corradini, V., Eichenlaub, U., Batrla, R., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.01.010 · Cited by 808
“Unfortunately, the currently available CSF assays for Ab(1–42), pTau, and tTau are limited by considerable variability between laboratories and assay batches [20,21].”
BackgroundSelf-citation
Metadata
- Authors
- Mattsson, N., Andreasson, U., Persson, S., Arai, H., Batish, S. D., Bernardini, S., Bocchio‐Chiavetto, L., Blankenstein, M. A., Carrillo, M. C., Chalbot, S., Coart, E., Chiasserini, D., Cutler, N., Dahlfors, G., Duller, S., Fagan, A. M., Forlenza, O., Frisoni, G. B., Galasko, D., Galimberti, D., Hampel, H., Handberg, A., Heneka, M. T., Herskovits, A. Z., Herukka, S., Holtzman, D. M., Humpel, C., Hyman, B. T., Iqbal, K., Jucker, M., Kaeser, S. A., Kaiser, E., Kapaki, E., Kidd, D., Klivenyi, P., Knudsen, C. S., Kummer, M. P., Lui, J., LladÓ, A., Lewczuk, P., Li, Q., Martins, R., Masters, C., McAuliffe, J., Mercken, M., Moghekar, A., Molinuevo, J. L., Montine, T. J., Nowatzke, W., O'Brien, R., Otto, M., Paraskevas, G. P., Parnetti, L., Petersen, R. C., Prvulovic, D., de Reus, H. P. M., Rissman, R. A., Scarpini, E., Stefani, A., Soininen, H., Schröder, J., Shaw, L. M., Skinningsrud, A., Skrogstad, B., Spreer, A., Talib, L., Teunissen, C., Trojanowski, J. Q., Tumani, H., Umek, R. M., Van Broeck, B., Vanderstichele, H., Vecsei, L., Verbeek, M. M., Windisch, M., Zhang, J., Zetterberg, H., & Blennow, K.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2011-07
- Volume
- 7
- Issue
- 4
- Pages
- 386
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2132066584
- Cited by
- 413
- References
- 68
- FWCI
- 25.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.